Biopharmaceutical Services Ireland Facility Expanded to Offer More Capacity and Improved Timelines for Challenge Studies
At our Ballina, Ireland facility, we now offer additional BSL-2 containment for clients working on new treatments in vaccine development.
Vaccines have gained tremendous attention in the global effort to combat pathogens. Regardless of the pathogen, studies must be conducted to assess the potency and efficacy of potential vaccines. Designing and developing vaccines requires the use of challenge studies, which involve vaccinating an animal and then challenging them with a target pathogen.
Due to the infectious nature of most pathogens there are critical regulations to address. Enormously important to Charles River is the humane and ethical care of animals. Thus, animal ethics and safety considerations are a priority during such studies.
Expansion of Ballina Facility
Designing an animal challenge study that translates to humans must take into consideration many factors, such as route of infection, infectious dose, permissive animal species, vaccine formulation, biomarkers, immune responses and disease end points. Currently, Charles River is conducting in vivo challenge studies with various BSL-2 pathogens. BPS Ireland has recently expanded its facility and service portfolio to offer BSL-2 in vivo challenge studies (bacterial and viral).
What does the BPS Ireland facility expansion at Ballina mean to you and your research programs? See below for a list of benefits:
For more information about the BPS Ireland facility expansion at Ballina, please contact us at firstname.lastname@example.org or 1.877.CRIVER.1.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
Charles River has developed and optimized the RT-PCR test for vertically-transmitted poultry pathogens for testing SPF flocks as defined by the PhEur 5.2.2.
May 20–May 22
Please visit Charles River tabletop #611 to discuss our full portfolio of products and services, including our Preclinical Services, as well as our Biopharmaceutical Services, which deliver client-focused solutions for the specific testing and manufacturing requirements of your biologic.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.